Skip to main content
Pharmanutra logo

Pharmanutra — Investor Relations & Filings

Ticker · PHN ISIN · IT0005274094 LEI · 815600F8217BC7733697 XMIL Manufacturing
Open in API
Filings indexed 601 across all filing types
Latest filing 2020-09-08 M&A Activity
Country IT Italy
Listing XMIL PHN

About Pharmanutra

http://www.pharmanutra.it

PharmaNutra is a company operating in the pharmaceutical and nutraceutical sectors, focused on the development and distribution of nutritional supplements and medical devices. Grounded in scientific research, the company creates innovative solutions for health and wellness. Its core activities center on addressing nutritional deficiencies, particularly iron, through proprietary functional ingredients and technologies. The product portfolio also extends to supporting muscle and joint health, sports nutrition, and applications across various therapeutic areas, including gynecology, orthopedics, hematology, and gastroenterology. The company emphasizes the development of effective and safe products supported by clinical evidence.

Recent filings

Filing Released Lang Actions
PR PHN - distribution agreement Alesco and Deltagen UK 08_09_2020
M&A Activity Classification · 1% confidence The document is an official communication (Informazione Regolamentata) dated September 8, 2020, announcing a new exclusive distribution agreement between Alesco S.r.l. (a PharmaNutra subsidiary) and Deltagen UK for Atura brand plant proteins in Italy. This type of announcement, detailing a significant commercial agreement, partnership, or strategic development that is material to the company's operations and market position, fits best under the category of general corporate news or regulatory filings that are not specifically financial reports (10-K, IR, ER) or management changes (MANG). Since it is a specific business development announcement, and not a general regulatory filing fallback (RNS), it is most closely aligned with a significant corporate event. However, none of the provided codes perfectly capture a 'Material Commercial Agreement Announcement'. Given the options, this is a significant corporate update. It is not a standard financial report, earnings release, or management change. It is a specific business development. In the absence of a dedicated 'Material Event' or 'Contract Announcement' code, and noting that it is a formal communication (Informazione Regolamentata) detailing a strategic move, it is best classified as a general Regulatory Filing (RNS) as it is a mandatory disclosure of a material event, or potentially a Capital/Financing Update (CAP) if the agreement implies a major shift in business structure, but the core is the agreement itself. Given the nature of the disclosure (a press release about a new distribution deal), RNS is the most appropriate fallback for material, non-standard announcements.
2020-09-08 English
CS PHN - accordo tra Alesco e Deltagen UK 08_09_2020
Regulatory Filings Classification · 1% confidence The document is an official communication identified by the header 'Informazione Regolamentata n. 20106-28-2020' and a reception date of '08 Settembre 2020'. The subject is 'CS PHN - accordo tra Alesco e Deltagen' (Agreement between Alesco and Deltagen). The content details a new exclusive distribution agreement for plant proteins under the Atura brand. This type of announcement, concerning a significant business development (a new commercial agreement/partnership), is typically classified as a general regulatory announcement or a specific corporate action announcement. Since there is no specific category for 'Commercial Agreement' and it is not a financial report (10-K, IR, ER), nor a management change (MANG), nor a capital event (CAP, SHA), it falls best under the general regulatory filing category, RNS, as it is a material, non-financial disclosure required by the market regulator (AIM Italia). It is not a Report Publication Announcement (RPA) because it is the substance of the news, not just an announcement that a report is available.
2020-09-08 Italian
CS PHN - dati vendita 27082020
Earnings Release Classification · 1% confidence The document is a press release from PharmaNutra S.p.A. dated August 27, 2020. The subject line is 'CS PHN - dati vendita 27082020' (CS PHN - sales data 08/27/2020). The content details sales performance and market share data for the first half of 2020, comparing it to the previous year, and includes quotes from the President. This type of announcement, focusing on key financial highlights for a specific period (H1 2020) immediately following the period's end, aligns perfectly with the definition of an Earnings Release (ER). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), but rather the initial announcement of results. H1 2020
2020-08-27 Italian
CS PHN - 3 anni di AIM 20_07_2020
Regulatory Filings Classification · 1% confidence The document is a press release dated July 20, 2020, titled "CS PHN - 3 anni di AIM 20_07_2020" (CS PHN - 3 years on AIM 20_07_2020). It celebrates the third anniversary of PharmaNutra's listing on the AIM Italia market, detailing performance metrics, growth, and future plans. The document structure, use of the term 'Comunicato Stampa' (implied by the context and structure, and confirmed by the 'CS' in the subject line), and the nature of the content (a general corporate update/celebration) strongly suggest it is a general regulatory announcement rather than a specific financial report (like 10-K or IR) or a specific corporate action filing (like DIV or CAP). Since it is a formal, time-sensitive announcement released via the regulatory channel (indicated by 'Informazione Regolamentata'), and it doesn't fit the definitions for ER, CT, or other specific reports, the most appropriate classification is the general regulatory announcement category, RNS (Regulatory Filings). The document length is substantial (over 12k characters), so it is not an RPA.
2020-07-20 Italian
CS - PHN Anticipazione ricavi primo semestre 2020
Earnings Release Classification · 1% confidence The document is an 'Informazione Regolamentata' (Regulated Information) from Pharmanutra S.p.A. The subject ('Oggetto') is 'CS - PHN Anticipazione ricavi primo semestre 2020' (Press Release - PHN Revenue forecast first half 2020). The text explicitly states preliminary consolidated revenues for the first half of 2020, showing a +17% increase compared to the previous year. Crucially, it mentions: 'I risultati complessivi e dettagliati saranno diffusi a seguito del Consiglio di Amministrazione chiamato all'approvazione della relazione finanziaria semestrale in data 14 settembre 2020.' This indicates the document is an early announcement of key financial figures (revenue highlights) before the full, detailed semi-annual report is approved and released. This aligns perfectly with the definition of an Earnings Release (ER), which covers initial announcements of periodical financial results (key highlights only). It is not the full Interim/Quarterly Report (IR) because the detailed results are pending approval. H1 2020
2020-07-14 Italian
CS - PHN art 17 regolamento aim italia 16_06_2020
Major Shareholding Notification Classification · 1% confidence The document is an official communication ('COMUNICATO STAMPA') issued on June 16, 2020, by Pharmanutra S.p.A. The subject explicitly states it is a 'COMUNICAZIONE AI SENSI DELL'ART. 17 DEL REGOLAMENTO EMITTENTI AIM ITALIA' (Communication pursuant to Art. 17 of the AIM Italia Issuers Regulation). The content details a change in significant shareholding, specifically a notification received from Kairos Partners SGR S.p.A. that their stake dropped below the 5% threshold, and it subsequently lists the current major shareholders holding over 5%. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2020-06-16 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.